Advertisement


Danh Pham, MD: Lung Cancer Screening Rates Still Too Low

2018 ASCO Annual Meeting

Advertisement

Danh Pham, MD, of the James Graham Brown Cancer Center, University of Louisville, discusses his findings using a registry on the low rates of screening with low-dose computed tomography, despite its potential to prevent thousands of lung cancer deaths each year (Abstract 6504).



Related Videos

Leukemia
Immunotherapy

Peter Hillmen, MB, ChB, on CLL: Results From the MURANO Trial

Peter Hillmen, MB, ChB, of St James’s University Hospital, discusses phase III study findings on minimal residual disease negativity with venetoclax plus rituximab in relapsed or r...

Lung Cancer

Tony Mok, MD, on NSCLC: Results From the ARCHER 1050 Trial

Tony Mok, MD, of the Chinese University of Hong Kong, discusses study findings on dacomitinib vs gefitinib for first-line treatment of advanced non–small cell lung cancer, a final ...

Issues in Oncology
Immunotherapy

Lee S. Schwartzberg, MD, on Using Immunotherapy in the Community Setting: 2018 Update on an ACCC Program

Lee S. Schwartzberg, MD, of West Cancer Center, reports on the progress of the ACCC Immuno-Oncology Institute to speed adoption of immunotherapeutics in community practices.

Leukemia

William G. Wierda, MD, PhD, and Julie M. Vose, MD, MBA, on CLL: Results From the CAPTIVATE Trial

Julie M. Vose, MD, MBA, of the University of Nebraska Medical Center, and William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, discuss...

Hematologic Malignancies
Immunotherapy

Meletios A. Dimopoulos, MD, on Waldenström’s Macroglobulinemia

Meletios A. Dimopoulos, MD, of the National and Kapodistrian University of Athens, discusses phase III findings on ibrutinib/rituximab vs placebo/rituximab in Waldenström’s macrogl...

Advertisement

Advertisement



;
Advertisement